Sugi Predict

Sugi Predict / Compounds / SCHEMBL105644

SCHEMBL105644

SCHEMBL105644

O=C(O)C1(C(=O)Nc2ccc(F)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.48
▸ MET P08581 8/20 0.48
▸ GAA P10253 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ FAAH O00519 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ KDR P35968 2/20 0.46
▸ AXL P30530 2/20 0.46
▸ RET P07949 1/20 0.46
▸ KIT P10721 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ MERTK Q12866 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280125 0.98 MET (0.47) ALDH1A1METGAANPC1RAB9A
SCHEMBL372046 0.93 FAAH (0.48) ALDH1A1METGAANPC1RAB9A
SCHEMBL12468984 0.91 ALDH1A1 (0.53) ALDH1A1METGAAHDAC1KDR
SCHEMBL558092 0.88 POLB (0.55) METNPC1RAB9AFAAHKDR
SCHEMBL19370182 0.88 MET (0.46) ALDH1A1METFAAHKDRAXL
4-Aminophenol SCHEMBL374608 0.87 MET (0.46) ALDH1A1METGAARAB9AKDR
SCHEMBL2286282 0.86 ALDH1A1 (0.48) ALDH1A1METGAANPC1RAB9A
SCHEMBL14742411 0.85 IDO1 (0.45) ALDH1A1METGAANPC1RAB9A
SCHEMBL23982911 0.84 ALDH1A1 (0.47) ALDH1A1METGAAFAAHHDAC1
SCHEMBL407809 0.84 ALDH1A1 (0.56) ALDH1A1METGAAHDAC1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 820 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979544-B Preparation method of cabozitinib or salt thereof 江苏先声药业有限公司 2024-06-28 — — CN claimed
US-20240190825-A1 PROCESS FOR PREPARATION OF CABOZANTINIB BIOCON LIMITED (IN) 2024-06-13 — — US claimed
EP-4313048-A1 PROCESS FOR PREPARATION OF CABOZANTINIB Biocon Limited (IN) 2024-02-07 — — EP claimed
WO-2023222946-A1 PROCESS FOR THE PREPARATION OF CABOZANTINIB FERMION OY (FI) 2023-11-23 — — WO claimed
US-11498902-B2 Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof NATCO PHARMA LIMITED (IN) 2022-11-15 — — US claimed
WO-2022201079-A1 PROCESS FOR PREPARATION OF CABOZANTINIB BIOCON LIMITED (IN) 2022-09-29 — — WO claimed
US-20210188776-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF NATCO PHARMA LIMITED (IN) 2021-06-24 — — US claimed
CN-112979544-A Preparation method of cabozantinib or salt thereof 江苏先声药业有限公司 2021-06-18 — — CN claimed
CN-111217745-B Preparation method of cabozantinib 漯河医学高等专科学校 2021-05-11 — — CN claimed
CN-111217745-A Preparation method of cabozantinib 漯河医学高等专科学校 2020-06-02 — — CN claimed
EP-3551612-A1 PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF MSN Laboratories Private Limited, R&D Center (IN) 2019-10-16 — — EP claimed
CN-104370811-B A kind of novel crystal forms of quinoline compound and preparation method thereof 广东东阳光药业有限公司 2019-02-12 — — CN claimed
WO-2018104954-A1 PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2018-06-14 — — WO claimed
CN-122036603-A Preparation method of anti-tumor drug cabatinib 新乡学院 2026-05-15 — — CN disclosed
EP-4143169-B1 PROCESSES FOR THE PREPARATION OF A KINASE INHIBITOR EXELIXIS INC (US) 2026-04-15 — — EP disclosed
US-20260049059-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB SYNTHON BV (NL) 2026-02-19 — — US disclosed
WO-2006004833-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
US-20060004006-A1 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-01-05 — — US disclosed
US-20050288290-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-29 — — US disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288290-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 ALDH1A1 3087/4885MET 721/4885GAA 1488/4885
US-20240190825-A1 PROCESS FOR PREPARATION OF CABOZANTINIB PDK1, PDHB, MPC2 ALDH1A1 1148/4885MET 197/4885GAA 992/4885
US-20060004006-A1 Pyrrolotriazine kinase inhibitors MAP3K5, MAP3K15, MAP4K2 ALDH1A1 3818/4885MET 2109/4885GAA 2824/4885
US-20260049059-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB KRAS, PDGFRB, BRAF ALDH1A1 637/4885MET 5/4885GAA 1950/4885
US-20210188776-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FIP1L1, FGFR1, RCC1 ALDH1A1 316/4885MET 619/4885GAA 1672/4885
US-11498902-B2 Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof FIP1L1, ABL1, FGFR1 ALDH1A1 218/4885MET 597/4885GAA 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.